PDF(Sci-hub)
Abstract：
Preclinical studies with tofacitinib demonstrated teratogenic effects. Data about effects on human fetuses are limited and current recommendations are to immediately discontinue the treatment. Our purpose is to report a case of exposure to tofacitinib during the first trimester of pregnancy.
A 40-year-old woman with psoriatic arthritis became pregnant during the first month of treatment with tofacitinib. Tofacitinib was interrupted immediately, and parents were informed about the possible risks of teratogenicity. At the end of pregnancy, our patient gave birth to a healthy newborn.
All the available evidence of tofacitinib exposure during pregnancy in humans belongs to outcomes of unexpected pregnancies in the context of clinical trials and post-marketing cases. This case may contribute to enriching available data about teratogenic risks of tofacitinib exposure during pregnancy.
A 40-year-old woman with psoriatic arthritis became pregnant during the first month of treatment with tofacitinib. Tofacitinib was interrupted immediately, and parents were informed about the possible risks of teratogenicity. At the end of pregnancy, our patient gave birth to a healthy newborn.
All the available evidence of tofacitinib exposure during pregnancy in humans belongs to outcomes of unexpected pregnancies in the context of clinical trials and post-marketing cases. This case may contribute to enriching available data about teratogenic risks of tofacitinib exposure during pregnancy.
摘要：
托法替尼的临床前研究证明了致畸作用。有关对人类胎儿影响的数据有限，目前的建议是立即停止治疗。我们的目的是报告在怀孕的头三个月期间暴露于托法替尼的病例。
一名患有银屑病关节炎的40岁女性在使用托法替尼治疗的第一个月内怀孕。托法替尼立即中断,父母被告知可能的致畸性风险.在怀孕结束时,我们的病人生下了一个健康的新生儿。
在临床试验和上市后病例中，人类怀孕期间托法替尼暴露的所有现有证据都属于意外怀孕的结果。这种情况可能有助于丰富有关怀孕期间托法替尼暴露的致畸风险的现有数据。
一名患有银屑病关节炎的40岁女性在使用托法替尼治疗的第一个月内怀孕。托法替尼立即中断,父母被告知可能的致畸性风险.在怀孕结束时,我们的病人生下了一个健康的新生儿。
在临床试验和上市后病例中，人类怀孕期间托法替尼暴露的所有现有证据都属于意外怀孕的结果。这种情况可能有助于丰富有关怀孕期间托法替尼暴露的致畸风险的现有数据。
